(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
30 November 2006 (30.11.2006)

PCT

(10) International Publication Number
WO 2006/127584 A1

(51) International Patent Classification:
C07D 471/04 (2006.01) *A61K 31/506* (2006.01)
A61K 31/437 (2006.01) *A61P 29/00* (2006.01)
A61K 31/444 (2006.01)

(21) International Application Number:
PCT/US2006/019708

(22) International Filing Date: 22 May 2006 (22.05.2006)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/683,509 20 May 2005 (20.05.2005) US

(71) Applicant *(for all designated States except US)*: **ELAN PHARMACEUTICALS, INC.** [US/US]; 800 Gateway Blvd., South San Francisco, CA 94080 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **STAPPENBECK, Frank** [US/US]; 1411 6th Avenue, West Seattle, WA 98119 (US). **KONRADI, Andrei** [US/US]; 30 Victoria Road, Burlingame, CA 94010 (US). **JAGODZINSKI, Jacek** [US/US]; 1485 Kentifield Avenue, Redwood City, CA 95061 (US). **SEMKO, Christopher, M.** [US/US]; 4993 Norris Road, Fremont, CA 94536 (US). **XU, Ying-zi** [US/US]; 793 Cereza Drive, Palo Alto, CA 94306 (US). **SMITH, Jenifer, L.** [US/US]; 512 Cortesti Drive, South San Francisco, CA 94080 (US). **ROSSITER, Kassandra** [US/US]; 5510 Century Park Way, San Jose, CA 9511 (US).

(74) Agent: **SARUSSI, Steven, J.**; MCDONNELL BOEHNEN HULBERT & BERGHOFF LLP, 300 South Wacker Drive, Suite 3200, Chicago, IL 60606 (US).


(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: IMIDAZOLONE PHENYLALANINE DERIVATIVES AS VLA-4 ANTAGONISTS



(I)

(57) Abstract: Disclosed are compounds of the f ormula : and the pharmaceutically acceptable salts thereof wherein the variables A, n, R^5, R^{21}-R^{24} and Q are defined herein. These compounds bind VLA-4. Certain of these compound also inhibit leukocyte adhesion and, in particular, leukocyte adhesion mediated by VLA-4. Such compounds are useful in the treatment of inflammatory diseases in a mammalian patient, e.g., human, such as asthma, Alzheimer's disease, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, tissue transplantation, tumor metastasis and myocardial ischemia. The compounds can also be administered for the treatment of inflammatory brain diseases such as multiple sclerosis.

WO 2006/127584 A1